OLMA
Price:
$11.83
Market Cap:
$677.46M
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2020-11-19
Stock Exchange
NASDAQ
Ticker
OLMA
According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.80. This represents a change of -2.03% compared to the average of -5.92 of the last 4 quarters.
The mean historical PE Ratio of Olema Pharmaceuticals, Inc. over the last ten years is -144.38. The current -5.80 PE Ratio has changed 301.73% with respect to the historical average. Over the past ten years (40 quarters), OLMA's PE Ratio was at its highest in in the December 2022 quarter at -0.98. The PE Ratio was at its lowest in in the December 2019 quarter at -169.82.
Average
-144.38
Median
-44.80
Minimum
-456.05
Maximum
-0.96
Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 587.60%
Maximum Annual PE Ratio = -0.96
Minimum Annual Increase = -93.71%
Minimum Annual PE Ratio = -456.05
Year | PE Ratio | Change |
---|---|---|
2023 | -6.57 | 587.60% |
2022 | -0.96 | -81.70% |
2021 | -5.22 | -93.71% |
2020 | -83.03 | -81.79% |
2019 | -456.05 | 45.03% |
The current PE Ratio of Olema Pharmaceuticals, Inc. (OLMA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.25
5-year avg
-110.36
10-year avg
-144.38
Olema Pharmaceuticals, Inc.’s PE Ratio is less than Sana Biotechnology, Inc. (-4.82), greater than Cullinan Oncology, Inc. (-6.96), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Molecular Partners AG (-2.67), less than Mineralys Therapeutics, Inc. (-4.63), less than AN2 Therapeutics, Inc. (-0.47), greater than Pharvaris N.V. (-8.20), less than PepGen Inc. (-3.22), greater than Gracell Biotechnologies Inc. (-12.26), less than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Design Therapeutics, Inc. (-5.23), less than Erasca, Inc. (-3.94), greater than Disc Medicine, Inc. (-14.19), greater than Larimar Therapeutics, Inc. (-8.80), less than Fennec Pharmaceuticals Inc. (54.24), less than Orchestra BioMed Holdings, Inc. (-3.61), less than Nuvectis Pharma, Inc. (-4.95), greater than Centessa Pharmaceuticals plc (-9.93),
Company | PE Ratio | Market cap |
---|---|---|
-4.82 | $1.12B | |
-6.96 | $1.04B | |
-2.33 | $131.12M | |
-1.08 | $210.48M | |
-2.67 | $182.90M | |
-4.63 | $558.43M | |
-0.47 | $30.44M | |
-8.20 | $1.03B | |
-3.22 | $287.77M | |
-12.26 | $989.87M | |
-3.19 | $181.50M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-3.94 | $807.96M | |
-14.19 | $1.50B | |
-8.80 | $513.64M | |
54.24 | $144.76M | |
-3.61 | $212.20M | |
-4.95 | $115.27M | |
-9.93 | $1.62B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Olema Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Olema Pharmaceuticals, Inc. (OLMA)?
What is the highest PE Ratio for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 3-year average PE Ratio for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 5-year average PE Ratio for Olema Pharmaceuticals, Inc. (OLMA)?
How does the current PE Ratio for Olema Pharmaceuticals, Inc. (OLMA) compare to its historical average?